Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet syndrome.